Baird Downgrades Embark Technology to Neutral, Lowers Price Target to $3

Baird analyst Ben Kallo downgrades Embark Technology (NASDAQ:EMBK) from Outperform to Neutral and lowers the price target from $15 to $3.

Baird analyst Ben Kallo downgrades Embark Technology (NASDAQ:EMBK) from Outperform to Neutral and lowers the price target from $15 to $3.

Total
0
Shares
Related Posts
Read More

Reported Late Monday, MediciNova Receives A Notice Of Allowance For A New Patent Covering MN-001 And MN-002 For The Treatment Of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia In Brazil

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has received a Notice of Allowance

MNOV